Publication: Glucocorticoid receptor changes its cellular location with breast cancer development
Loading...
Date
2008
Authors
Conde, Isabel ; Paniagua, Ricardo ; Fraile, Benito ; Lucio, Javier ; Arenas, María I.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Glucocorticoids play a major role in
attenuation of the inflammatory response and they are
useful in the primary combination chemotherapy of
breast cancer, since in vitro studies have demonstrated an
antiproliferative effect in human breast cancer cells. In
contrast, it was recently shown that glucocorticoids
protect against apoptotic signals evoked by cytokines,
cAMP, tumour suppressors, and death genes in
mammary gland epithelia. Their actions are mediated by
intracellular receptor (GR) that functions as a hormonedependent
transcription factor; however, no previous
studies have been focused on GR expression in different
pathologies of the human breast, and the possible
relationship with that of mineralocorticoid receptor
(MR) and COX-2. Also, the role of these proteins on
tumoral breast epithelial cells remains unclear.
Therefore, we examined GR, MR and COX-2 expression
by immunohistochemistry and Western blot techniques
in 142 samples of human breast obtained by total or
partial mastectomy. We found that the percentage of
positive patients presenting nuclear immunoreaction to
GR decreased with tumor development, while all
samples analyzed showed cytoplasmic immunoreactions to MR. All positive samples to COX-2 antibody showed
cytoplasmic location, a higher immunoreaction being
observed in benign breast diseases than in carcinomatous
lesions. Thus, breast cancer progression is associated
with the accumulation of GR in the cytoplasm of
tumoral cells and the decrease of COX-2 expression.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.